Irbesartan Hctz Fair-Med

Irbesartan, the active ingredient in Irbesartan Hctz Fair-Med, is an angiotensin II receptor blocker presented as a combination tablet for oral use. It treats hypertension in adult patients by relaxing blood vessels and reducing fluid retention.

GNH USA supplies Irbesartan Hctz Fair-Med as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan/Hydrochlorothiazide acts on the renin‑angiotensin‑aldosterone system and renal sodium handling to lower blood pressure in hypertensive patients.

- Essential hypertension: reduces systolic and diastolic pressure to target levels. - Hypertension with fluid retention: improves control by adding diuretic‑induced natriuresis. - Patients needing combination therapy: achieves blood‑pressure goals when monotherapy is insufficient.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue or weakness - Increased urinary frequency - Electrolyte disturbances (e.g., low potassium) - Mild rise in serum creatinine

Serious or Rare Side Effects: - Severe dehydration or electrolyte imbalance - Acute kidney injury or significant rise in creatinine - Hyperkalemia, especially with potassium‑sparing agents - Anaphylactic or severe allergic reactions - Pancreatitis - Blood dyscrasias such as agranulocytosis

Before initiating therapy, clinicians should assess renal function, electrolyte status, and blood pressure response.

- Monitor blood pressure regularly: adjust therapy if target not reached. - Check renal function and serum electrolytes: especially potassium and creatinine. - Use caution in patients with hepatic impairment: dose may need adjustment. - Avoid in severe dehydration or volume depletion: may worsen hypotension. - Counsel diabetic patients: diuretic effect can affect glucose control. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan/HCTZ can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Concomitant use with aliskiren in diabetic patients: increased risk of renal impairment. - Potassium‑sparing diuretics or supplements: risk of hyperkalemia. - NSAIDs (e.g., ibuprofen, naproxen): may reduce antihypertensive effect and impair renal function. - Lithium: thiazide component can raise lithium levels, leading to toxicity. - Other potent antihypertensives: additive hypotensive effect.

Moderate Interactions (Monitor Closely): - CYP2C9 inhibitors (e.g., fluconazole): may increase irbesartan plasma concentrations. - Additional thiazide or loop diuretics: risk of excessive diuresis and electrolyte loss. - Antidiabetic agents: thiazide may raise blood glucose, requiring dose adjustment. - Warfarin: monitor INR as thiazide can affect anticoagulation control. - Digoxin: monitor serum levels due to potential changes in renal clearance.